Norges Bank Takes $7.96 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Norges Bank acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNFree Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 275,140 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,963,000. Norges Bank owned 0.50% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of SUPN. Barclays PLC lifted its holdings in shares of Supernus Pharmaceuticals by 1.9% during the third quarter. Barclays PLC now owns 54,844 shares of the specialty pharmaceutical company’s stock valued at $1,511,000 after purchasing an additional 1,021 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Supernus Pharmaceuticals by 1.1% during the third quarter. Swiss National Bank now owns 119,700 shares of the specialty pharmaceutical company’s stock valued at $3,300,000 after purchasing an additional 1,300 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals during the third quarter valued at $341,000. State of New Jersey Common Pension Fund D lifted its holdings in shares of Supernus Pharmaceuticals by 8.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 78,148 shares of the specialty pharmaceutical company’s stock valued at $2,155,000 after purchasing an additional 5,854 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Supernus Pharmaceuticals by 12.7% during the third quarter. Deutsche Bank AG now owns 27,304 shares of the specialty pharmaceutical company’s stock valued at $753,000 after purchasing an additional 3,082 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 1.4 %

Shares of Supernus Pharmaceuticals stock opened at $27.15 on Friday. The stock has a 50-day moving average price of $29.78 and a 200 day moving average price of $29.33. The company has a market cap of $1.49 billion, a P/E ratio of -93.62 and a beta of 0.93. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $35.96.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler reduced their target price on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th.

View Our Latest Stock Analysis on Supernus Pharmaceuticals

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 3,884 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the completion of the sale, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $282,724.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $282,724.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total value of $436,572.84. Following the completion of the transaction, the vice president now directly owns 8,570 shares in the company, valued at $302,606.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,739 shares of company stock valued at $1,076,383. Corporate insiders own 8.76% of the company’s stock.

About Supernus Pharmaceuticals

(Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Recommended Stories

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.